Purdue Pharma L.P. today announced that the company's Board of Directors has appointed Mark Timney as President and Chief Executive Officer.
"We found a proven leader in Mark Timney," said Dr. Raymond Sackler, co-founder and board member of Purdue. "I am confident that his capabilities and experience, coupled with Purdue's culture of excellence, will grow our business and strengthen our healthcare industry leadership." Mark brings more than 20 years of pharmaceutical sales and marketing experience to Purdue, including success in designing and executing strategies to achieve market leadership. Prior to joining Purdue, he was President of Merck US, where he managed Sales & Marketing, Managed Markets, and Payers. With Mark's guidance, Purdue will continue advancing breakthrough research and development initiatives and pioneering new commercial models.
"I'm honored to begin this new journey at Purdue Pharma, the industry leader in developing innovative medicines to relieve the burden of pain," said Mark Timney. "I look forward to working with Purdue's exceptional colleagues to achieve long-term success by broadening our pain management portfolio." During Mark's tenure in the US market, he achieved a record of strong financial growth; launched several key products; led transformational business development; and played a key role in pipeline governance.
Before coming to the United States, Mark served for seven years as Merck's Country Manager in Korea and then Japan. Prior to that, he held leadership positions for more than four years at Merck Australia.
Before joining Merck, he spent eight years in sales and marketing at a number of multinational pharmaceutical companies, including Zeneca in New Zealand, ICI Pharmaceuticals in Australia, and Roussel Labs in the United Kingdom.
Mark Timney succeeds John Stewart, who has retired from Purdue.